Clinical course and damage index in systemic lupus erythematosus
https://doi.org/10.14412/1996-7012-2025-4-81-85
Abstract
This review examines the various types of systemic lupus erythematosus (SLE) course. It discusses the challenges in predicting disease flares and the heterogeneity of SLE progression. Special attention is given to the damage index, which correlates with long-term outcomes and patients’ quality of life.
About the Authors
P. A. Sholkina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Polina Andreevna Sholkina,
34A, Kashirskoye Shosse, Moscow 115522
A. A. Shumilova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoye Shosse, Moscow 115522
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoye Shosse, Moscow 115522;
2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Nasonova VA. Systemic Lupus Erythematosus. Moscow; 1972.
2. Reshetnyak TM. Systemic lupus erythematosus. In: Badokin VV, editor. Rheumatology. Clinical lectures. Moscow: Litera; 2012; P. 245-331.
3. Maffi M, Tani C, Cascarano G, et al. Which extra-renal flare is 'difficult to treat' in systemic lupus erythematosus? A one-year longitudinal study comparing traditional and machine learning approaches. Rheumatology (Oxford). 2024 Feb 1;63(2):376-384. doi: 10.1093/rheumatology/kead166.
4. Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999 Dec;42(12):2682-8. doi: 10.1002/1529-0131(199912)42:12 3.0.CO;2-6.
5. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43): S-99-104.
6. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1152-8. doi: 10.1002/art.24741.
7. Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish populationbased lupus cohort: an 8-year prospective study. Lupus. 2010 Mar;19(3):239-46. doi: 10.1177/0961203309351033. Epub 2009 Nov 27.
8. Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol. 2012 Nov-Dec;30(6): 856-63. Epub 2012 Dec 17.
9. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8): 1467-72.
10. Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford). 2012 Mar; 51(3):491-8. doi: 10.1093/rheumatology/ker368. Epub 2011 Nov 21.
11. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006 Aug;33(8):1570-7.
12. Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009 May; 48(5):542-5. doi: 10.1093/rheumatology/kep012. Epub 2009 Feb 20.
13. Yee CS, Gordon C, Akil M, et al. The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology (Oxford). 2023 Feb 1;62(2):668-675. doi: 10.1093/rheumatology/keac334.
14. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010 Jul;19(8):949-56. doi: 10.1177/0961203310366572. Epub 2010 Apr 7.
15. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020 Feb 18; 7(1):e000389. doi: 10.1136/lupus-2020-000389. eCollection 2020.
16. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus — a 5-yr prospective study. Rheumatology (Oxford). 2004 Aug;43(8): 1039-44. doi: 10.1093/rheumatology/keh238. Epub 2004 May 25.
17. Alarcon GS, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford). 2004 Feb;43(2):202-5. doi: 10.1093/rheumatology/keg481. Epub 2003 Aug 15.
18. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.
19. Mak A, Cheung MW, Chiew HJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012 Jun;41(6):830-9. doi: 10.1016/j.semarthrit.2011.11.002. Epub 2012 Jan 16.
20. Ajeganova S, Hafström I, Frostegard J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a casecontrol study over 10 years. Lupus Sci Med. 2021 Feb;8(1):e000454. doi: 10.1136/lupus2020-000454.
21. Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev. 2014 Jul;13(7):770-7. doi: 10.1016/j.autrev.2014.01.055. Epub 2014 Jan 27.
22. Elefante E, Gualtieri L, Schiliro D, et al. Impact of disease activity patterns on healthrelated quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE). Lupus Sci Med. 2024 Jul 29;11(2):e001202. doi: 10.1136/lupus-2024-001202.
23. Johnson SR, Gladman DD, Brunner HI, еt al. Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2023 May;75(5):998-1006. doi: 10.1002/acr.24849. Epub 2022 Dec 20.
24. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5): v29-v38. doi: 10.1093/rheumatology/keaa382.
25. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 Sep;30(9):1955-9.
26. Ramnarain A, Liam C, Milea D, et al. Predictors of Organ Damage in Systemic Lupus Erythematosus in the Asia Pacific Region: A Systematic Review. Arthritis Care Res (Hoboken). 2024 May;76(5):720-732. doi: 10.1002/acr.25291. Epub 2024 Feb 22.
27. Lopez-Villanueva RF, Valencia-Pacheco G, Zapata-Vazquez R, et al. Follow-up of clinical activity and accumulated organic damage in a cohort of patients with systemic lupus erythematosus from the Yucatбn Peninsula, Mexico (1995-2016). Reumatol Clin (Engl Ed). 2023 Feb;19(2):106-113. doi: 10.1016/j.reumae.2021.12.002. Epub 2022 Jun 23.
28. Elera-Fitzcarrald C, Gamboa-Cardenas RV, Reategui-Sokolova C, et al. The SLICC-FI Predicts Damage Accrual in SLE Patients. Data From the Almenara Lupus Cohort. Lupus. 2022 Nov;31(13):1666-1670. doi: 10.1177/09612033221126855. Epub 2022 Sep 27.
29. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020 Dec 5; 59(Suppl5):v69-v81. doi: 10.1093/rheumatology/keaa403.
30. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3): 560-4. doi: 10.3899/jrheum.080828. Epub 2009 Feb 4.
31. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7): 1145-53. doi: 10.1093/rheumatology/ker410. Epub 2012 Jan 23.
32. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012 Dec;64(12):4021-8. doi: 10.1002/art.34672.
33. Martin-Iglesias D, Paredes-Ruiz D, RuizIrastorza G. Use of Glucocorticoids in SLE: A Clinical Approach. Mediterr J Rheumatol. 2024 Jun 30;35(Suppl 2):342-353. doi: 10.31138/mjr.230124.uos. eCollection 2024 Jun.
34. Banjari M, Touma Z, Gladman DD. Improving measures of disease activity in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023 Feb;19(2):193-202. doi: 10.1080/1744666X.2023.2156339. Epub 2022 Dec 14.
35. Solovyeva ES, Aseeva EA, Lisitsyna TA, et al. Irreversible organ damages in pa-tients with systemic lupus erythematosus. SLICC damage index. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):56-62. (In Russ.).
36. Aseeva EA, Solovyev SK, Klyukvina NG, et al. Irreversible organ damages in a co-hort of patients with systemic lupus erythematosus (RENAISSANCE). Nauchno-prakticheskaya revmatologiya. 2016;54(4):404-411. (In Russ.).
Review
For citations:
Sholkina PA, Shumilova AA, Reshetnyak TM. Clinical course and damage index in systemic lupus erythematosus. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2025;19(4):81-85. (In Russ.) https://doi.org/10.14412/1996-7012-2025-4-81-85
Views:
33
Email this article 